2 completed, 2 recruiting. 2 Phase 4, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Recruiting 2 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow IPX203: new trials by email Literature Review of IPX203 trials Research Report on IPX203
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease CREXONT ER - Parkinson Disease | Phase 4 | Recruiting | The Cleveland Clinic | 22 | 2025-07-24 | 2026-10-15 |
| A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease CREXONT ER - Parkinson Disease | Phase 4 | Recruiting | Impax Laboratories, LLC | 220 | 2025-02-12 | 2025-08-24 |
| Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations IPX203 - Parkinson Disease | Phase 3 | Completed | Impax Laboratories, LLC | 419 | 2019-04-03 | 2023-07-13 |
| A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease Sinemet, IPX203 - Advanced Parkinson's Disease | Phase 2 | Completed | Impax Laboratories, LLC | 28 | 2016-11-14 | 2022-06-06 |
Impax Laboratories, LLC (3) · The Cleveland Clinic (1)
United States (4) · Czechia (1) · France (1) · Germany (1) · Italy (1) · Poland (1) · Spain (1) · United Kingdom (1)
Hester Visser, MD (1) · Hubert Fernandez, MD (1)
2018 (1)